CO2025001998A2 - Formas cristalinas de un inhibidor de la pcsk9, composiciones y usos - Google Patents

Formas cristalinas de un inhibidor de la pcsk9, composiciones y usos

Info

Publication number
CO2025001998A2
CO2025001998A2 CONC2025/0001998A CO2025001998A CO2025001998A2 CO 2025001998 A2 CO2025001998 A2 CO 2025001998A2 CO 2025001998 A CO2025001998 A CO 2025001998A CO 2025001998 A2 CO2025001998 A2 CO 2025001998A2
Authority
CO
Colombia
Prior art keywords
disease
compositions
crystal forms
methods
pcsk9 inhibitor
Prior art date
Application number
CONC2025/0001998A
Other languages
English (en)
Spanish (es)
Inventor
Jongrock Kong
Richard J Varsolona
Richard Desmond
Peter E Maligres
Fuh-Rong Tsay
Carlos Alberto Pons Siepermann
Artis Klapars
Lee Robison
Alfred Lee
Tiffany Piou
Lorenzo Codan
Patrick Larpent
Original Assignee
Merck Sharp & Dohme Llc
Werthenstein Biopharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc, Werthenstein Biopharma Gmbh filed Critical Merck Sharp & Dohme Llc
Publication of CO2025001998A2 publication Critical patent/CO2025001998A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2025/0001998A 2022-08-17 2025-02-25 Formas cristalinas de un inhibidor de la pcsk9, composiciones y usos CO2025001998A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263371690P 2022-08-17 2022-08-17
US202263384298P 2022-11-18 2022-11-18
PCT/US2023/072326 WO2024040125A1 (en) 2022-08-17 2023-08-16 Crystalline forms of a pcsk9 inhibitor, compositions and uses

Publications (1)

Publication Number Publication Date
CO2025001998A2 true CO2025001998A2 (es) 2025-03-17

Family

ID=89942405

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2025/0001998A CO2025001998A2 (es) 2022-08-17 2025-02-25 Formas cristalinas de un inhibidor de la pcsk9, composiciones y usos

Country Status (10)

Country Link
US (1) US20260035411A1 (cg-RX-API-DMAC7.html)
EP (1) EP4573104A4 (cg-RX-API-DMAC7.html)
JP (1) JP7866141B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250048468A (cg-RX-API-DMAC7.html)
CN (1) CN119731194A (cg-RX-API-DMAC7.html)
AU (1) AU2023325144A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025001998A2 (cg-RX-API-DMAC7.html)
IL (1) IL319006A (cg-RX-API-DMAC7.html)
MX (1) MX2025001887A (cg-RX-API-DMAC7.html)
WO (1) WO2024040125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026032253A1 (zh) * 2024-08-06 2026-02-12 石药集团中奇制药技术(石家庄)有限公司 环肽类似物及其制备方法和用途
WO2026101894A1 (en) * 2024-11-07 2026-05-15 Merck Sharp & Dohme Llc Process for preparing a peptide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250161677A (ko) 2018-06-21 2025-11-17 머크 샤프 앤드 돔 엘엘씨 Pcsk9 길항제 화합물
EP3810129B1 (en) 2018-06-21 2023-08-16 Merck Sharp & Dohme LLC Pcsk9 antagonist bicyclo-compounds
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
EP4021919A1 (en) * 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds

Also Published As

Publication number Publication date
EP4573104A4 (en) 2026-08-05
WO2024040125A1 (en) 2024-02-22
AU2023325144A1 (en) 2025-01-30
MX2025001887A (es) 2025-03-07
JP2025527471A (ja) 2025-08-22
EP4573104A1 (en) 2025-06-25
CN119731194A (zh) 2025-03-28
JP7866141B2 (ja) 2026-05-26
US20260035411A1 (en) 2026-02-05
KR20250048468A (ko) 2025-04-08
IL319006A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
CL2022002985A1 (es) Inhibidores de pi3k y métodos de uso de los mismos
CO2024006030A2 (es) Compuestos de quinolina como inhibidores de kras
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
CR20110452A (es) Inhibidores de la poli (adp-ribosa) polimerasa (parp)
CL2008001659A1 (es) Compuestos derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad inmunologica seleccionada a partir de rechazo de trasplante de organo, lupus, esclerosis multiple, entre otras enfermedades.
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
CO6382119A2 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
BRPI0512237A (pt) cis-imidazolinas
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
EP4316603A3 (en) 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
AR128108A1 (es) Indoles, indazoles y análogos relacionados para inhibir yap / taz-tead
MX2025001887A (es) Formas cristalinas de un inhibidor de pcsk9, composiciones y usos
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
CO2024009582A2 (es) Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap/taz tead
CL2022003400A1 (es) Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
CL2007002652A1 (es) Compuestos derivados de isoserina, inhibidores del factor de coagulacion de la sangre ixa; procedimiento de preparacion; y su uso para preparar un medicamento para tratar enfermedades acompanadas de trombosis, embolias, hipercoagulabilidad o cambios
UY38971A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2021011858A (es) Inhibidores de aldosa reductasa.
GT200500026A (es) Derivados de beta-aminoacidos como inhibidores del factor xa.
AR081514A1 (es) El compuesto 4-[etil(dimetil)amonio]butanoato, el metodo para la preparacion del mismo y el uso en el tratamiento de la enfermedad cardiovascular